-
Novo Nordisk Shanghai signed a contract with Shanghai Pharmaceutical Holdings The cooperation will achieve another breakthrough
Time of Update: 2022-12-30
Xiaping Zhou, Senior Vice President and President of Greater China, Novo Nordisk, said: "This investment is an important step for Novo Nordisk to realize the new layout of the 'dual center, three engines' whole industry chain, which will further strengthen the business capabilities of the trade and innovation center in Shanghai, support the development of Shanghai's pharmaceutical trade, and better serve Chinese patients.
-
Complement drugs are full of smoke! Novartis, AstraZeneca, Sanofi, Roche prepare
Time of Update: 2022-12-30
Rare diseases have always been the field of onslaught by multinational big pharmaceutical companies, and the market competition around "orphan drugs" has never lacked stories. Novartis has announced
-
Pharmaceutical biology is optimistic, and these companies have been frequently investigated recently
Time of Update: 2022-12-30
js?cdnversion='+~(-new Date()/36e5)];In the past week, the number of listed companies surveyed by disclosed institutions reached 190 (compared to 205 in the previous week), focusing on machinery and equipment, medicine and biology, electronics, basic chemicals, computers, automobiles and other industries.
-
6 varieties of more than 1 billion proprietary Chinese medicines lead the way and 38 exclusive varieties dominate the screen
Time of Update: 2022-12-30
Recently, the State Administration of Traditional Chinese Medicine issued the "Guidelines for Home Medicine Intervention for People Infected with the New Coronavirus Infection", and 60 proprietary Chi
-
The myopia drug market is just rushing to the beach, and many pharmaceutical companies have entered the market!
Time of Update: 2022-12-30
News on December 15, Xingqi Eye Medicine announced the completion of the 1-year phase III clinical trial summary report of atropine sulfate eye drops.
News on December 15, Xingqi Eye Medicine announced the completion of the 1-year phase III clinical trial summary report of atropine sulfate eye drops.
-
26 domestic chemical drugs of Class 1 new drugs were accepted, Hengrui, Beida, Dongguang Pharmaceutical...
Time of Update: 2022-12-30
Declaration of chemical drugs Class 1 domestic production In November, CDE accepted a total of 54 domestic Class 1 new drugs (according to the acceptance number), all of which were IND applications, involving 26 varieties (statistics by drug + enterprise dimension), and most of the acceptance numbers have entered the corresponding sequence to queue for review; The following table shows the Class 1 new drugs newly produced in November.
-
Announcement of the State Food and Drug Administration on the Implementation of Electronic Declaration of Drug Registration Applications (No. 110 of 2022)
Time of Update: 2022-12-30
In order to improve the efficiency of drug review and approval, the State Food and Drug Administration has decided to implement electronic submission of application materials for drug registration, and the specific requirements are announced as follows:1.
-
Pharmacopoeia: Guidelines for the determination of powder flowability published
Time of Update: 2022-12-30
The most common method for determining static rest angle can be classified based on the following two important experimental variables: The height of the powder through the "funnel" is fixed relative to the chassis, or its height can change with the formation of the cone.
-
Last week, a large number of pharmaceutical companies were reduced by shareholders
Time of Update: 2022-12-30
js?cdnversion='+~(-new Date()/36e5)];This year's wave of reduction is sweeping the pharmaceutical circle, and a large number of listed pharmaceutical companies are announcing the reduction of shareholders or executives one after another, including WuXi AppTec, Inco Medical, Aotai Biologics, Huasen Pharmaceutical, Aviron and so on.
-
Thousands of dollars of new crown Indian generic drugs sold out? Be careful!
Time of Update: 2022-12-30
National HealthIndustry Co On the 17th, according to the "Dahe News Yu Video" report, hospitals in Zhengzhou have opened the sale of domestic new crown oral drug azvudine, which is 330 yuan per bottle and can be purchased on prescription at the fever clinic.
-
The "homecoming wave" is coming, how to ensure primary medical services?
Time of Update: 2022-12-30
Key groups are divided into three categories to carry out health services Nie Chunlei, director of the Department of Primary Health of the National Health Commission, introduced that providing classified and graded services for the elderly with underlying diseases can use limited medical resources for the most needed people, avoid unnecessary waste of medical resources, and improve the efficiency and quality of medical services.
-
Domestic pharmaceutical enterprises are vigorously promoting the construction of industrialization bases, and investment of 100 million yuan has become the norm
Time of Update: 2022-12-30
With the wave of innovation in the pharmaceutical industry, many enterprises are accelerating projects such as building new R&D production bases in order to improve profitability, enhance innovative
-
6 varieties of more than 1 billion proprietary Chinese medicines lead the way and 38 exclusive varieties dominate the screen
Time of Update: 2022-12-30
Recently, the State Administration of Traditional Chinese Medicine issued the "Guidelines for Home Medicine Intervention for People Infected with the New Coronavirus Infection", and 60 proprietary Ch
-
CDE issued four announcements, including "Technical Guidelines for Bioequivalence Research of Amphotericin B Liposomes for Injection"
Time of Update: 2022-12-30
The Drug Review Center of the State Food and Drug Administration issued the "Technical Guidelines for Bioequivalence Research of Amphotericin B Liposomes for Injection", "Technical Guidelines for Bio
-
In December, a number of IPOs were applied for and listed in the pharmaceutical industry
Time of Update: 2022-12-30
According to the company's announcement on December 2, all the shares issued this time are new shares, the initial number of shares issued is 15 million, and the total share capital after issuance is 83.
-
Fosun Pharma plans to acquire European companies! Baekje, Junsil, Hwang, Boteng... Why has Europe become the "dream place" of Chinese pharmaceutical companies?
Time of Update: 2022-12-30
At the same time, Fosun Pharma further stated that by accelerating the layout of overseas industrial chains, the mature products and manufacturing division will increase the development of special dosage forms, adapt to centralized procurement, transform the marketing model of generic drugs, and promote the transformation of Gland Pharma into biological drug CDMO, complex preparations and difficult injections, as well as the registration process of products in China.
-
On the same day, there was good news about the launch of 2 new drugs
Time of Update: 2022-12-30
js?cdnversion='+~(-new Date()/36e5)];With the introduction and landing of a series of policy documents to encourage drug innovation and implement priority review and approval, while China's innovative drug industry is booming, the efficiency of review and approval of new drugs at home and abroad is also constantly improving.
-
New rules for marketing authorization holders open for comments! There are special requirements for the audit of pharmaceutical packaging material suppliers and the post-marketing change control system of drugs
Time of Update: 2022-12-30
In addition, Article 23 [Requirements for Drug Safety Incidents] stipulates that in the event of a safety incident related to drug quality, the holder shall immediately take effective measures to dispose of the relevant drugs and their raw materials, excipients, packaging materials and containers and relevant production lines that directly contact drugs, so as to prevent the harm from expanding.
-
The stock prices of Yiling Pharmaceutical, Northeast Pharmaceutical, Xinhua Pharmaceutical, etc. soared in December! How long can the "hoarding market" last?
Time of Update: 2022-12-30
Recently, the market demand for antipyretic and analgesic drugs has exploded, and Xinhua Pharmaceutical, the leading A-share ibuprofen API, is hot, with a stock price of 8 boards in 10 days, a five-day increase of 83.
-
Domestic API enterprises are actively exploring the European market, and many drugs have obtained CEP certificates
Time of Update: 2022-12-30
Lunan Pharmaceutical announced on August 29 that the company received the European Pharmacopoeia Certificate of Applicability of Zoledronic Acid API issued by the European Medicines Quality Agency.
